Literature DB >> 10978261

The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study.

J Hulthe1, L Bokemark, J Wikstrand, B Fagerberg.   

Abstract

An operative definition of the metabolic syndrome has been suggested by a working group associated with the World Health Organization in 1998. The aim of this study was to examine whether small, low density lipoprotein (LDL) particle size was associated with the metabolic syndrome and with subclinical atherosclerosis as measured by ultrasound in the carotid and femoral arteries. The study was performed in a population-based sample of clinically healthy men (N=391), all 58 years old and not undergoing any treatment with cardiovascular drugs. Exclusion criteria were cardiovascular or other clinically overt diseases or continuous medication with cardiovascular drugs. The results showed that subjects characterized by the metabolic syndrome (n=62) had a thicker mean intima-media complex (IMT) in both the carotid and femoral arteries (0.86 versus 0.77 mm, P:<0.001, and 1.03 versus 1. 00 mm, P:=0.022, respectively) and also lower mean values for LDL particle size (25.78 versus 26.80 nm, respectively, P:<0.001) compared with subjects with no risk factors (n=77). The group with the metabolic syndrome (n=62) also had higher mean values for serum cholesterol and heart rate. In the whole study group (N=391), there were significant but weak negative relationships between small LDL particle size, increasing IMT, and increasing cross-sectional intima-media area of the carotid and femoral arteries and also negative relationships between LDL particle size and plaque occurrence and size in the carotid and femoral arteries. In summary, this is the first large-scale study to demonstrate a relationship between the clustering of risk factors that constitute the metabolic syndrome and a small LDL particle size pattern and the occurrence of preclinical atherosclerosis in the carotid and femoral arteries, as assessed by the ultrasound technique, in healthy 58-year-old men recruited from the general population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10978261     DOI: 10.1161/01.atv.20.9.2140

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  38 in total

1.  World Health Organization-defined metabolic syndrome is a better predictor of coronary calcium than the adult treatment panel III criteria in American men aged 40-49 years.

Authors:  Tomoko Takamiya; Wahid R Zaky; Daniel Edmundowics; Takashi Kadowaki; Hirotsugu Ueshima; Lewis H Kuller; Akira Sekikawa
Journal:  Diabetes Care       Date:  2004-12       Impact factor: 19.112

2.  The operative risk factors in the metabolic syndrome: is it lipids and high BP or are there direct vascular effects of insulin resistance and obesity.

Authors:  Fabrice M A C Martens; Frank L J Visseren
Journal:  Curr Diab Rep       Date:  2007-02       Impact factor: 4.810

3.  Association between small dense LDL and sub-clinical atherosclerosis in patients with psoriatic arthritis.

Authors:  Marco Gentile; Rosario Peluso; Matteo Nicola Dario Di Minno; Luisa Costa; Francesco Caso; Biagio de Simone; Gabriella Iannuzzo; Raffaele Scarpa; Paolo Rubba
Journal:  Clin Rheumatol       Date:  2016-07-13       Impact factor: 2.980

4.  Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.

Authors:  B Fagerberg; S Edwards; T Halmos; J Lopatynski; H Schuster; S Stender; G Stoa-Birketvedt; S Tonstad; S Halldórsdóttir; I Gause-Nilsson
Journal:  Diabetologia       Date:  2005-07-07       Impact factor: 10.122

5.  The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol.

Authors:  Irene F Gazi; Theodosios D Filippatos; Vasilis Tsimihodimos; Vasilios G Saougos; Evangelos N Liberopoulos; Dimitri P Mikhailidis; Alexandros D Tselepis; Moses Elisaf
Journal:  Lipids       Date:  2006-07       Impact factor: 1.880

6.  Genetics of non-conventional lipoprotein fractions.

Authors:  Alexis C Frazier-Wood
Journal:  Curr Genet Med Rep       Date:  2015-08-29

7.  Low-density lipoprotein particle size in hepatic steatosis and metabolic syndrome.

Authors:  Dal-Sik Kim; Young-Kon Kim; Do-Sung Kim; Han-Jung Chae; Tae-Sun Park; Young I Cho; Seul-Ki Jeong
Journal:  Diabetol Metab Syndr       Date:  2010-03-22       Impact factor: 3.320

8.  Association of Metabolic Syndrome and C-reactive Protein Levels with Intracranial Atherosclerotic Stroke.

Authors:  Oh Young Bang; Mi Ae Lee; Jae Hyuk Lee; Ji Won Kim; Phil Hyu Lee; In Soo Joo; Kyoon Huh
Journal:  J Clin Neurol       Date:  2005-04-30       Impact factor: 3.077

9.  Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS).

Authors:  Xue-Qiao Zhao; Richard A Krasuski; Jefferson Baer; Edwin J Whitney; Blazej Neradilek; Alan Chait; Santica Marcovina; John J Albers; B Greg Brown
Journal:  Am J Cardiol       Date:  2009-12-01       Impact factor: 2.778

10.  Increased mean carotid intima media thickness in type 2 diabetes mellitus patients with non-blood pressure component metabolic syndrome: A preliminary report.

Authors:  Marwan S M Al-Nimer; Ismail I Hussein
Journal:  Int J Diabetes Dev Ctries       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.